Other substances

Famotidine

A histamine H2-receptor antagonist.

Phase of research

Potential treatment - clinical evidence

How it helps

Unknown

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
19
 AI-suggested references
14
 Clinical trials

General information

Famotidine is a histamine H2-receptor antagonist. It reduces gastric acid secretion and is therefore used as an antacid (NCIt).

Famotidine on DrugBank
Famotidine on PubChem
Famotidine on Wikipedia


Synonyms

Pepcid

Marketed as

FAMOTIDINE; PEPCID; FLUXID; ULCIDINE and other

 

Structure image - Famotidine

C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N

Supporting references

Link Tested on Impact factor Notes Publication date
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Cohort study 		Patients 17.37

In patients hospitalized with COVID-19 and not initially intubated, famotidine use was associated with a 2-fold reduction in clinical deterioration leading to intubation or death.

 May/01/2020
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients
Severe severity Small molecule Critical severity Cohort study 		Patients 2.68

In combination with cetirizine reduced progression in symptom severity. Sample size: 110. Dosage: 20 mg twice daily. Endpoints: Increase in the rate of discharge; reduction in ventilation requirements; reduction in inpatient mortality rate; reduction in duration of hospitalization.


 Aug/29/2020

AI-suggested references

Link Publication date
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.
May/14/2021
Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19.
Dec/23/2020
Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm
May/16/2022
The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.
Apr/05/2021
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Feb/10/2022
Experimental Search for New Means of Pathogenetic Therapy COVID-19: Inhibitor of H2-Receptors Famotidine Increases the Effect of Oseltamivir on Survival and Immune Status of Mice Infected by A/PR/8/34 (H1N1)
Mar/05/2022
Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19
Dec/30/2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Jun/04/2020
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
Apr/18/2022
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
Jan/21/2022
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.
Mar/23/2021
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
Aug/28/2020
The association between famotidine and in-hospital mortality of patients with COVID-19
Oct/11/2021
Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis
Jun/16/2021
Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19.
Sep/28/2020
Famotidine inhibits Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV2 infection
Jun/30/2021
Histamine Potentiates SARS-CoV-2 Spike Protein Entry Into Endothelial Cells.
Apr/25/2022
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease
Jun/29/2020
Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective
Apr/01/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04389567 Famotidine Outpatient COVID-19 Treatment Study Completed May/12/2020 May/25/2020
  • Alternative id - 1605914-1
  • Interventions - Drug: Famotidine
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 10
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptomatic improvement|Peripheral blood oxygen saturation
NCT05122208 Famotidine in Covid-19 Intensive Care Unit Completed Mar/20/2020 Aug/15/2021
  • Alternative id - istanbulMU intensive care
  • Interventions - Drug: Famotidine Tablets
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Istanbul Medeniyet University, İ̇stanbul, Turkey
  • Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
  • Enrollment - 60
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Mortality|Entubation|Laboratory parameterr
NCT05043350 Combined Antihistaminics Therapy in COVID 19 Patients Not yet recruiting Phase 2|Phase 3 Sep/13/2021 Jan/13/2022
  • Alternative id - ACUCFPASURHDIRB2020110301REC43
  • Interventions - Drug: Loratadine|Drug: Famotidine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 214
  • Age - Child, Adult, Older Adult
  • Outcome measures - Assessment of number of patients requiring Mechanical ventilator
NCT04545008 Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19 Terminated Phase 1 Oct/20/2020 Jun/02/2021
  • Alternative id - Pro00100394
  • Interventions - Drug: Famotidine|Drug: N-Acetyl cysteine
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Prisma Health Baptist Easley Hospital, Easley, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Greer Memorial Hospital, Greer, South Carolina, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0|Rate of Hospitalization|Time to Symptom Resolution
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Recruiting Phase 2 Jul/31/2020 Nov/01/2022
  • Alternative id - I-SPY-COVID
  • Interventions - Drug: Remdesivir|Drug: Pulmozyme|Drug: IC14|Drug: Celecoxib Famotidine|Drug: Narsoplimab|Drug: Aviptadil Acetate|Drug: Cyclosporine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|UC Davis Medical Center, Davis, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Main Line Health - Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality
NCT04504240 Role of Famotidine in the Clinical Improvement of COVID-19 Patients. Completed Phase 3 Aug/01/2020 Apr/15/2021
  • Alternative id - 10000753/980
  • Interventions - Drug: Famotidine 20 MG
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinājpur, Bangladesh
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 208
  • Age - 16 Years to 80 Years   (Child, Adult, Older Adult)
  • Outcome measures - Time to Clinical Improvement (TTCI)|Time to symptomatic recovery.|Mortality Rate|Duration of ICU Stay.|Total hospital stay.|Time to clinical failure or death.|Time to Viral clearance / COVID-19 recovery.
NCT04370262 Multi-site Adaptive Trials for COVID-19 Completed Phase 3 Apr/07/2020 Sep/07/2020
  • Alternative id - 20-0268
  • Interventions - Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 233
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity
NCT04621149 An Outpatient Study Investigating Non-prescription Treatments for COVID-19 Recruiting Phase 2 Nov/15/2020 Mar/31/2021
  • Alternative id - Profact-01
  • Interventions - Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extract
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - AZ Good Health Center, Tempe, Arizona, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 20 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Reduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body Temperature
NCT04724720 Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19 Active, not recruiting Phase 2 Jan/19/2021 Dec/01/2021
  • Alternative id - 20-1155
  • Interventions - Drug: Famotidine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Northwell Health, Lake Success, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 56
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Cumulative incidence of symptom resolution|Rate of symptom resolution|Relative change of symptoms|Assessment of Serious Adverse Events|Clinical improvement|Improvement in peripheral oxygen saturation|Mortality|Comparative proportions of hospitalized patients|Change in systemic inflammation
NCT04836806 Cetirizine and Famotidine for COVID-19 Withdrawn Phase 4 Aug/01/2021 Jul/01/2022
  • Alternative id - STUDY00001722
  • Interventions - Drug: Cetirizine and Famotidine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Emory University Hospital at Wesley Woods COVID-19 Testing Facility, Atlanta, Georgia, United States|Emory Healthcare Network Peachtree Immediate Care COVID-19 Testing Centers, Atlanta, Georgia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to resolution of symptoms|Severity of Symptoms|Time to Resolution of Individual Symptoms|Incidence of Hospitalization|Incidence of Intensive Care Unit (ICU) Admission|Incidence of Death
NCT04565392 Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19) Withdrawn Phase 4 May/01/2021 Jan/31/2022
  • Alternative id - Pykonsult 201
  • Interventions - Drug: Famotidine 20 milligram tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Pykonsult headquarters, New Fairfield, Connecticut, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Course Binary Outcome|Serious Adverse Events|Time to symptomatic recovery|SCL18 (self-check list of 18 symptoms of COVID-19)|Patient's Global Impression of Change|Adverse Events|Day-60 Follow-up
NCT05085574 Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Not yet recruiting Phase 2 Jan/01/2022 Nov/01/2022
  • Alternative id - LDOS-21-001-01
  • Interventions - Drug: Famotidine|Drug: Celecoxib|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 404
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time-to-event to achieve WHO level ≤3|Death rate|Hospital discharge to chronic palliative care|Hospital discharge with no additional medical care|Related adverse events (AEs) and serious adverse events (SAEs)|Study discontinuation due to related AEs or SAEs
NCT05077332 LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Active, not recruiting Phase 2 Dec/29/2021 Nov/01/2022
  • Alternative id - LDOS-21-001
  • Interventions - Drug: Famotidine|Drug: Celecoxib|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - US02-04: Integrated Health Solutions, Miami, Florida, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 2000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - (LDOS-21-001-01) Time-to-event to achieve WHO level ≤3|(LDOS-21-001-01) All-Cause Mortality rate|(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to increased COVID-19 symptom severity|(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to death (all-cause mortality)
NCT05077969 Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Recruiting Phase 2 Dec/29/2021 Nov/01/2022
  • Alternative id - LDOS-21-001-02
  • Interventions - Drug: Famotidine|Drug: Celecoxib|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Integrated Therapeutic Solutions USA, Inc., Newport Beach, California, United States|Integrated Therapeutic Solutions USA, Inc., Miami, Florida, United States|Integrated Health Solutions USA, Inc., Atlanta, Georgia, United States|Integrated Therapeutic Solutions USA, Inc., Chicago, Illinois, United States|Integrated Therapeutic Solutions USA, Inc, Gaithersburg, Maryland, United States|Integrated Therapeutic Solutions USA, Inc., Newark, New Jersey, United States|Integrated Therapeutic Solutions USA, Inc., New York, New York, United States|Integrated Therapeutic Solutions USA, Inc., Huntingdon, Pennsylvania, United States|Integrated Therapeutic Solutions USA, Inc., Charleston, South Carolina, United States|Integrated Therapeutic Solutions USA, Inc., Dallas, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 1465
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients with at least one COVID-19-related medically attended contact due to increased COVID-19 symptom severity|Number of patients with at least one COVID-19-related medically attended contact due to death (all-cause mortality).|Incidence of Treatment-Emergent Serious Adverse Events (SAE) as assessed by participant withdrawal|Incidence of death
Export (.csv)